{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:58:07Z","timestamp":1789351087245,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,2,16]],"date-time":"2013-02-16T00:00:00Z","timestamp":1360972800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s11940-013-0219-8","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T14:51:21Z","timestamp":1360939881000},"page":"424-438","source":"Crossref","is-referenced-by-count":57,"title":["Treatment of Huntington Disease"],"prefix":"10.1007","volume":"15","author":[{"given":"Aleksandar","family":"Videnovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,16]]},"reference":[{"key":"219_CR1","doi-asserted-by":"crossref","unstructured":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72(6):971\u201383.","DOI":"10.1016\/0092-8674(93)90585-E"},{"issue":"8","key":"219_CR2","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/01.WNL.0000086373.32347.16","volume":"61","author":"N Mahant","year":"2003","unstructured":"Mahant N, McCusker EA, Byth K, Graham S. Huntington's disease: clinical correlates of disability and progression. Neurology. 2003;61(8):1085\u201392.","journal-title":"Neurology"},{"issue":"4","key":"219_CR3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jmg.30.4.289","volume":"30","author":"L Maio Di","year":"1993","unstructured":"Di Maio L, Squitieri F, Napolitano G, et al. Onset symptoms in 510 patients with Huntington's disease. J Med Genet. 1993;30(4):289\u201392.","journal-title":"J Med Genet."},{"issue":"3","key":"219_CR4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp.71.3.310","volume":"71","author":"JS Paulsen","year":"2001","unstructured":"Paulsen JS, Ready RE, Hamilton JM, et al. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry. 2001;71(3):310\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"219_CR5","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1001\/archneur.55.10.1313","volume":"55","author":"I Litvan","year":"1998","unstructured":"Litvan I, Paulsen JS, Mega MS, Cummings JL. Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. Arch Neurol. 1998;55(10):1313\u20139.","journal-title":"Arch Neurol"},{"issue":"12","key":"219_CR6","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/01.WNL.0000098878.47789.BD","volume":"61","author":"AK Ho","year":"2003","unstructured":"Ho AK, Sahakian BJ, Brown RG, et al. Profile of cognitive progression in early Huntington's disease. Neurology. 2003;61(12):1702\u20136.","journal-title":"Neurology"},{"issue":"10","key":"219_CR7","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1212\/WNL.45.10.1867","volume":"45","author":"KA Bamford","year":"1995","unstructured":"Bamford KA, Caine ED, Kido DK, et al. A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates. Neurology. 1995;45(10):1867\u201373.","journal-title":"Neurology"},{"issue":"1","key":"219_CR8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/1531-8257(200001)15:1<173::AID-MDS1032>3.0.CO;2-T","volume":"15","author":"HH Fernandez","year":"2000","unstructured":"Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington's disease. Mov Disord. 2000;15(1):173\u20136.","journal-title":"Mov Disord"},{"issue":"12","key":"219_CR9","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/mds.20235","volume":"19","author":"M Tommaso de","year":"2004","unstructured":"de Tommaso M, Specchio N, Sciruicchio V, et al. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov Disord. 2004;19(12):1516\u20138.","journal-title":"Mov Disord"},{"issue":"3","key":"219_CR10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Huntington Study Group","year":"2006","unstructured":"Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366\u201372. Important recent Class I evidence treatment study on TBZ in HD.","journal-title":"Neurology"},{"key":"219_CR11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2377-9-62","volume":"9","author":"S Frank","year":"2009","unstructured":"Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group\/TETRA-HD Investigators. BMC Neurol. 2009;9:62.","journal-title":"BMC Neurol"},{"issue":"1","key":"219_CR12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/mds.21161","volume":"22","author":"C Kenney","year":"2007","unstructured":"Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007;22(1):10\u20133.","journal-title":"Mov Disord"},{"issue":"2","key":"219_CR13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","volume":"48","author":"J Jankovic","year":"1997","unstructured":"Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48(2):358\u201362.","journal-title":"Neurology"},{"issue":"6","key":"219_CR14","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00002826-200211000-00003","volume":"25","author":"WG Ondo","year":"2002","unstructured":"Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol. 2002;25(6):300\u20132.","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"219_CR15","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1212\/WNL.35.10.1450","volume":"35","author":"WC Koller","year":"1985","unstructured":"Koller WC, Trimble J. The gait abnormality of Huntington's disease. Neurology. 1985;35(10):1450\u20134.","journal-title":"Neurology"},{"issue":"8","key":"219_CR16","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/jnnp.47.8.848","volume":"47","author":"F Girotti","year":"1984","unstructured":"Girotti F, Carella F, Scigliano G, et al. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. J Neurol Neurosurg Psychiatry. 1984;47(8):848\u201352.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"558","key":"219_CR17","first-page":"114","volume":"83","author":"AW McArthur","year":"1976","unstructured":"McArthur AW, Pollock M, Smidt NA. Combined therapy with tetrabenazine and pimozide in Huntington's chorea: pilot study. N Z Med J. 1976;83(558):114\u20136.","journal-title":"N Z Med J."},{"issue":"1","key":"219_CR18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/jnnp.63.1.35","volume":"63","author":"JP Vugt van","year":"1997","unstructured":"van Vugt JP, Siesling S, Vergeer M, et al. Clozapine vs placebo in Huntington's disease: a double blind randomized comparative study. J Neurol Neurosurg Psychiatry. 1997;63(1):35\u20139. Class I evidence treatment study on clozapine in HD.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"219_CR19","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1212\/WNL.44.5.821","volume":"44","author":"U Bonuccelli","year":"1994","unstructured":"Bonuccelli U, Ceravolo R, Maremmani C, et al. Clozapine in Huntington's chorea. Neurology. 1994;44(5):821\u20133.","journal-title":"Neurology"},{"issue":"2","key":"219_CR20","first-page":"169","volume":"27","author":"N Vallette","year":"2001","unstructured":"Vallette N, Gosselin O, Kahn JP. Efficacy of clozapine in the course of Huntington chorea: apropos of a clinical case. Encephale. 2001;27(2):169\u201371.","journal-title":"Encephale"},{"issue":"5","key":"219_CR21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1212\/WNL.45.5.1023","volume":"45","author":"C Colosimo","year":"1995","unstructured":"Colosimo C, Cassetta E, Bentivoglio AR, Albanese A. Clozapine in Huntington's disease. Neurology. 1995;45(5):1023\u20134.","journal-title":"Neurology"},{"issue":"5","key":"219_CR22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002826-200209000-00007","volume":"25","author":"RM Bonelli","year":"2002","unstructured":"Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington's disease: an open label study. Clin Neuropharmacol. 2002;25(5):263\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"219_CR23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00004714-200104000-00023","volume":"21","author":"G Bogelman","year":"2001","unstructured":"Bogelman G, Hirschmann S, Modai I. Olanzapine and Huntington's disease. J Clin Psychopharmacol. 2001;21(2):245\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"219_CR24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1468-1331.2002.0354f.x","volume":"9","author":"RM Bonelli","year":"2002","unstructured":"Bonelli RM, Niederwieser G, Diez J, Koltringer P. Riluzole and olanzapine in Huntington's disease. Eur J Neurol. 2002;9(2):183\u20134.","journal-title":"Eur J Neurol"},{"issue":"2","key":"219_CR25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00004850-200203000-00009","volume":"17","author":"RM Bonelli","year":"2002","unstructured":"Bonelli RM, Niederwieser G, Tribl GG, Koltringer P. High-dose olanzapine in Huntington's disease. Int Clin Psychopharmacol. 2002;17(2):91\u20133.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"219_CR26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/jnnp.67.1.123","volume":"67","author":"HC Dipple","year":"1999","unstructured":"Dipple HC. The use of olanzapine for movement disorder in Huntington's disease: a first case report. J Neurol Neurosurg Psychiatry. 1999;67(1):123\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3B","key":"219_CR27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1590\/S0004-282X1999000500021","volume":"57","author":"EC Etchebehere","year":"1999","unstructured":"Etchebehere EC, Lima MC, Passos W, et al. Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report. Arq Neuropsiquiatr. 1999;57(3B):863\u20136.","journal-title":"Arq Neuropsiquiatr."},{"issue":"13","key":"219_CR28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM200009283431316","volume":"343","author":"VE Grove Jr","year":"2000","unstructured":"Grove Jr VE, Quintanilla J, DeVaney GT. Improvement of Huntington's disease with olanzapine and valproate. N Engl J Med. 2000;343(13):973\u20134.","journal-title":"N Engl J Med"},{"issue":"6","key":"219_CR29","first-page":"524","volume":"35","author":"FJ Jimenez-Jimenez","year":"2002","unstructured":"Jimenez-Jimenez FJ, de Toledo M, Puertas I, et al. Olanzapine improves chorea in patients with Huntington's disease. Rev Neurol. 2002;35(6):524\u20135.","journal-title":"Rev Neurol"},{"issue":"4","key":"219_CR30","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1590\/S0004-282X2004000600030","volume":"62","author":"J Laks","year":"2004","unstructured":"Laks J, Rocha M, Capitao C, et al. Functional and motor response to low dose olanzapine in Huntington's disease: case report. Arq Neuropsiquiatr. 2004;62(4):1092\u20134.","journal-title":"Arq Neuropsiquiatr."},{"issue":"4","key":"219_CR31","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881103174009","volume":"17","author":"RM Bonelli","year":"2003","unstructured":"Bonelli RM, Mayr BM, Niederwieser G, et al. Ziprasidone in Huntington's disease: the first case reports. J Psychopharmacol. 2003;17(4):459\u201360.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"219_CR32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mds.22376","volume":"24","author":"L Brusa","year":"2009","unstructured":"Brusa L, Orlacchio A, Moschella V, et al. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord. 2009;24(1):126\u20139.","journal-title":"Mov Disord"},{"key":"219_CR33","first-page":"1","volume":"5","author":"A Ciammola","year":"2009","unstructured":"Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington's disease: a case series. Neuropsychiatr Dis Treat. 2009;5:1\u20134.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"219_CR34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00004714-199704000-00023","volume":"17","author":"MA Parsa","year":"1997","unstructured":"Parsa MA, Szigethy E, Voci JM, Meltzer HY. Risperidone in treatment of choreoathetosis of Huntington's disease. J Clin Psychopharmacol. 1997;17(2):134\u20135.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"219_CR35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004714-199902000-00020","volume":"19","author":"C Dallocchio","year":"1999","unstructured":"Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol. 1999;19(1):101\u20133.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"219_CR36","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s00415-002-0741-1","volume":"249","author":"RM Bonelli","year":"2002","unstructured":"Bonelli RM, Niederwieser G. Quetiapine in Huntington's disease: a first case report. J Neurol. 2002;249(8):1114\u20135.","journal-title":"J Neurol"},{"issue":"5","key":"219_CR37","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.59.5.694","volume":"59","author":"L Verhagen Metman","year":"2002","unstructured":"Verhagen Metman L, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002;59(5):694\u20139.","journal-title":"Neurology"},{"issue":"12","key":"219_CR38","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/01.WNL.0000068165.07883.64","volume":"60","author":"C Lucetti","year":"2003","unstructured":"Lucetti C, Del Dotto P, Gambaccini G, et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology. 2003;60(12):1995\u20137.","journal-title":"Neurology"},{"issue":"3","key":"219_CR39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.63.3.597","volume":"63","author":"JM Heckmann","year":"2004","unstructured":"Heckmann JM, Legg P, Sklar D, et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology. 2004;63(3):597\u20138. author reply 597\u20138.","journal-title":"Neurology"},{"issue":"7","key":"219_CR40","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneur.60.7.996","volume":"60","author":"P O'Suilleabhain","year":"2003","unstructured":"O'Suilleabhain P, Dewey Jr RB. A randomized trial of amantadine in Huntington disease. Arch Neurol. 2003;60(7):996\u20138.","journal-title":"Arch Neurol"},{"issue":"7","key":"219_CR41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.parkreldis.2006.08.005","volume":"13","author":"WG Ondo","year":"2007","unstructured":"Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord. 2007;13(7):453\u20134.","journal-title":"Parkinsonism Relat Disord."},{"issue":"2","key":"219_CR42","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/01.wnl.0000169025.09670.6d","volume":"65","author":"BK Puri","year":"2005","unstructured":"Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 2005;65(2):286\u201392.","journal-title":"Neurology"},{"key":"219_CR43","doi-asserted-by":"crossref","unstructured":"Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol. 2008;65(12):1582\u20139.","DOI":"10.1001\/archneur.65.12.1582"},{"issue":"1","key":"219_CR44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.wnf.0000240945.44370.f0","volume":"30","author":"M Tommaso de","year":"2007","unstructured":"de Tommaso M, Difruscolo O, Sciruicchio V, et al. Two years' follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol. 2007;30(1):43\u20136.","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"219_CR45","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","volume":"67","author":"E Cubo","year":"2006","unstructured":"Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67(7):1268\u201371.","journal-title":"Neurology"},{"issue":"1","key":"219_CR46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/1531-8257(200001)15:1<173::AID-MDS1032>3.0.CO;2-T","volume":"15","author":"HH Fernandez","year":"2000","unstructured":"Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington's disease. Mov Disord. 2000;15(1):173\u20136.","journal-title":"Mov Disord"},{"issue":"3","key":"219_CR47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.870120319","volume":"12","author":"PG Como","year":"1997","unstructured":"Como PG, Rubin AJ, O'Brien CF, et al. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. Mov Disord. 1997;12(3):397\u2013401.","journal-title":"Mov Disord"},{"issue":"1","key":"219_CR48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/YIC.0b013e3283348018","volume":"25","author":"AK Holl","year":"2010","unstructured":"Holl AK, Wilkinson L, Painold A, et al. Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol. 2010;25(1):46\u201350.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"219_CR49","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1345\/aph.1C352","volume":"37","author":"RM Bonelli","year":"2003","unstructured":"Bonelli RM. Mirtazapine in suicidal Huntington's disease. Ann Pharmacother. 2003;37(3):452.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"219_CR50","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1212\/WNL.41.1.156","volume":"41","author":"M Sajatovic","year":"1991","unstructured":"Sajatovic M, Verbanac P, Ramirez LF, Meltzer HY. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. Neurology. 1991;41(1):156.","journal-title":"Neurology"},{"issue":"2","key":"219_CR51","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1468-1331.2002.0354e.x","volume":"9","author":"AK Erdemoglu","year":"2002","unstructured":"Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington's disease. Eur J Neurol. 2002;9(2):182\u20133.","journal-title":"Eur J Neurol"},{"issue":"4","key":"219_CR52","first-page":"347","volume":"6","author":"S Madhusoodanan","year":"1998","unstructured":"Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington's disease. Am J Geriatr Psychiatry. 1998;6(4):347\u20139.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"1","key":"219_CR53","first-page":"69","volume":"14","author":"F Squitieri","year":"2001","unstructured":"Squitieri F, Cannella M, Piorcellini A, et al. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(1):69\u201372.","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol."},{"issue":"6","key":"219_CR54","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1034\/j.1600-0404.2002.01197.x","volume":"105","author":"D Paleacu","year":"2002","unstructured":"Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand. 2002;105(6):441\u20134.","journal-title":"Acta Neurol Scand."},{"issue":"1","key":"219_CR55","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.psy.47.1.70","volume":"47","author":"M Alpay","year":"2006","unstructured":"Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. Psychosomatics. 2006;47(1):70\u20132.","journal-title":"Psychosomatics"},{"issue":"3","key":"219_CR56","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1176\/jnp.8.3.338","volume":"8","author":"NG Ranen","year":"1996","unstructured":"Ranen NG, Lipsey JR, Treisman G, Ross CA. Sertraline in the treatment of severe aggressiveness in Huntington's disease. J Neuropsychiatry Clin Neurosci. 1996;8(3):338\u201340.","journal-title":"J Neuropsychiatry Clin Neurosci."},{"issue":"4","key":"219_CR57","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0033-3182(97)71447-6","volume":"38","author":"AN Bhandary","year":"1997","unstructured":"Bhandary AN, Masand PS. Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders. Psychosomatics. 1997;38(4):389\u201391.","journal-title":"Psychosomatics"},{"issue":"7","key":"219_CR58","first-page":"1097","volume":"151","author":"A Byrne","year":"1994","unstructured":"Byrne A, Martin W, Hnatko G. Beneficial effects of buspirone therapy in Huntington's disease. Am J Psychiatry. 1994;151(7):1097.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"219_CR59","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0033-3182(93)71857-5","volume":"34","author":"RL Findling","year":"1993","unstructured":"Findling RL. Treatment of aggression in juvenile-onset Huntington's disease with buspirone. Psychosomatics. 1993;34(5):460\u20131.","journal-title":"Psychosomatics"},{"issue":"3","key":"219_CR60","first-page":"106","volume":"48","author":"JT Stewart","year":"1987","unstructured":"Stewart JT, Mounts ML, Clark Jr RL. Aggressive behavior in Huntington's disease: treatment with propranolol. J Clin Psychiatry. 1987;48(3):106\u20138.","journal-title":"J Clin Psychiatry."},{"issue":"9","key":"219_CR61","first-page":"385","volume":"48","author":"JT Stewart","year":"1987","unstructured":"Stewart JT. Paradoxical aggressive effect of propranolol in a patient with Huntington's disease. J Clin Psychiatry. 1987;48(9):385\u20136.","journal-title":"J Clin Psychiatry."},{"issue":"3","key":"219_CR62","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/jnnp.2009.202903","volume":"82","author":"GA Kang","year":"2011","unstructured":"Kang GA, Heath S, Rothlind J, Starr PA. Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington's disease. J Neurol Neurosurg Psychiatry. 2011;82(3):272\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"219_CR63","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3171\/JNS\/2008\/109\/7\/0130","volume":"109","author":"B Biolsi","year":"2008","unstructured":"Biolsi B, Cif L, Fertit HE, et al. Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus. J Neurosurg. 2008;109(1):130\u20132.","journal-title":"J Neurosurg"},{"issue":"9","key":"219_CR64","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/mds.22116","volume":"23","author":"A Fasano","year":"2008","unstructured":"Fasano A, Mazzone P, Piano C, et al. GPi-DBS in Huntington's disease: results on motor function and cognition in a 72-year-old case. Mov Disord. 2008;23(9):1289\u201392.","journal-title":"Mov Disord"},{"issue":"2","key":"219_CR65","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.20183","volume":"56","author":"E Moro","year":"2004","unstructured":"Moro E, Lang AE, Strafella AP, et al. Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol. 2004;56(2):290\u20134.","journal-title":"Ann Neurol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-013-0219-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-013-0219-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-013-0219-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T20:09:33Z","timestamp":1562702973000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-013-0219-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,16]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["219"],"URL":"https:\/\/doi.org\/10.1007\/s11940-013-0219-8","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,16]]}}}